Pzena Investment Management LLC Sells 8,018 Shares of Teleflex Incorporated $TFX

Pzena Investment Management LLC cut its stake in shares of Teleflex Incorporated (NYSE:TFX) by 2.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 379,465 shares of the medical technology company’s stock after selling 8,018 shares during the quarter. Pzena Investment Management LLC owned approximately 0.86% of Teleflex worth $46,310,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of TFX. AQR Capital Management LLC boosted its stake in Teleflex by 478.1% during the third quarter. AQR Capital Management LLC now owns 2,366,131 shares of the medical technology company’s stock worth $287,603,000 after acquiring an additional 1,956,811 shares in the last quarter. Abrams Bison Investments LLC bought a new position in shares of Teleflex in the third quarter valued at $112,317,000. Thrivent Financial for Lutherans lifted its stake in shares of Teleflex by 1,161.0% in the third quarter. Thrivent Financial for Lutherans now owns 550,449 shares of the medical technology company’s stock valued at $67,353,000 after buying an additional 506,796 shares in the last quarter. Capital International Investors bought a new position in shares of Teleflex in the third quarter valued at $44,851,000. Finally, Arrowstreet Capital Limited Partnership lifted its stake in shares of Teleflex by 123.9% in the third quarter. Arrowstreet Capital Limited Partnership now owns 660,800 shares of the medical technology company’s stock valued at $80,855,000 after buying an additional 365,663 shares in the last quarter. 95.62% of the stock is owned by institutional investors.

Teleflex Stock Performance

Shares of TFX stock opened at $131.77 on Friday. The firm has a 50-day moving average of $122.22 and a 200-day moving average of $116.82. The company has a market cap of $5.83 billion, a P/E ratio of -5.78, a P/E/G ratio of 1.01 and a beta of 0.82. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.55 and a quick ratio of 2.03. Teleflex Incorporated has a one year low of $100.18 and a one year high of $139.67.

Teleflex (NYSE:TFX) last announced its earnings results on Thursday, May 7th. The medical technology company reported $1.39 EPS for the quarter, beating the consensus estimate of $1.21 by $0.18. The company had revenue of $548.30 million during the quarter, compared to the consensus estimate of $536.91 million. Teleflex had a negative net margin of 35.88% and a positive return on equity of 13.29%. The firm’s revenue for the quarter was up 32.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.44 earnings per share. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. Equities research analysts forecast that Teleflex Incorporated will post 6.7 EPS for the current fiscal year.

Teleflex Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Monday, May 25th will be issued a $0.34 dividend. The ex-dividend date is Friday, May 22nd. This represents a $1.36 annualized dividend and a dividend yield of 1.0%. Teleflex’s dividend payout ratio is currently -5.96%.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on TFX. Raymond James Financial reaffirmed an “outperform” rating and issued a $150.00 price objective on shares of Teleflex in a research note on Friday, May 8th. Bank of America raised shares of Teleflex from an “underperform” rating to a “neutral” rating and set a $135.00 price objective on the stock in a research note on Monday, April 13th. Truist Financial reaffirmed a “hold” rating and issued a $143.00 price objective (up from $135.00) on shares of Teleflex in a research note on Monday, May 11th. Zacks Research raised shares of Teleflex from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 28th. Finally, Needham & Company LLC raised their price objective on shares of Teleflex from $138.00 to $147.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Three analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Teleflex has a consensus rating of “Hold” and an average price target of $144.00.

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.